Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Blood Advances|September 9, 2018
Enhancing immunotherapy of STING agonist for lymphoma in preclinical modelsAdrienne Sallets, Sophie Robinson, Adel Kardosh, et al.
Journal of Proteome Research|May 29, 2014
Comparative proteomics of short and tall glandular trichomes of Nicotiana tabacum reveals differential metabolic activitiesAdrienne Sallets, Maxime Beyaert, Marc Boutry, et al.
Cancer Research|February 9, 2022
Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic CancerWan Xing Hong, Idit Sagiv-Barfi, Debra K Czerwinski, et al.
Transgenic Research|November 6, 2010
Isolation of heat shock-induced Nicotiana tabacum transcription promoters and their potential as a tool for plant research and biotechnologyCatherine Navarre, Adrienne Sallets, Emilie Gauthy, et al.
Cancer Research|January 30, 2019
Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer ImmunityOle Audun Werner Haabeth, Timothy R Blake, Colin J McKinlay, et al.
Metabolic Engineering|July 17, 2016
Transient production of artemisinin in Nicotiana benthamiana is boosted by a specific lipid transfer protein from A. annuaBo Wang, Arman Beyraghdar Kashkooli, Adrienne Sallets, et al.
Bioconjugate Chemistry|March 30, 2023
Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the LungsTimothy R Blake, Ole A W Haabeth, Adrienne Sallets, et al.
Biorxiv : the Preprint Server for Biology|April 21, 2021
An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memoryOle A W Haabeth, Julian J K Lohmeyer, Adrienne Sallets, et al.
ACS Central Science|August 3, 2021
An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell MemoryOle A W Haabeth, Julian J K Lohmeyer, Adrienne Sallets, et al.
Molecular Therapy. Nucleic Acids|June 9, 2025
Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical modelsShruti Lal, Adrienne Sallets, Srinivasa R Bandi, et al.
Pageof 2